Rob Cascella

Robert A. Cascella joined the Neuronetics Board of Directors in April 2021. He has more than 30 years of experience in the healthcare industry in a range of senior management positions and has served on several boards.
Mr. Cascella joined Philips in 2015 and is currently a Special Advisor to the Company. Prior to this advisory role, he held the position of Executive Vice President and Strategic Business Development Leader at Royal Philips and was also a member of the company’s Executive Committee. Mr. Cascella has held several other leadership roles at Philips, including Chief Business Leader for the Precision Diagnosis Segment and Chief Business Leader of the Diagnosis and Treatment Segment. Over this period, Mr. Cascella was responsible for the turnaround of multiple lines of business and the completion of several strategic acquisitions.
Prior to Philips, Mr. Cascella spent ten years as President and later CEO of Hologic Inc., a global leader in women’s health. Over this period, Hologic grew from a $180 million capital equipment business to a $2.5 billion leader in women’s health.
Earlier in his career Mr. Cascella was a partner and executive committee member of CFG Capital, a boutique investment bank, where he represented the firm’s healthcare business. Over his career he has held various senior management positions ranging from CFO and VP Finance to President and COO for NeoVision, a breast ultrasound start-up company sold to US Surgical and Fischer Imaging.
Mr. Cascella has led or participated in over 15 acquisitions at an aggregate deal value of over $12 billion and has raised over $3 billion in debt and equity over his career. He holds a BA from Fairfield University. Currently he is on the Boards of Celestica (CLS: NYSE) a Canadian contract manufacturer and Metabolon a private company focused on the use of metabolomics for improved disease characterization.